Primary symptomatology in Alzheimer~s disease (AD) has been attributed to a presynaptic cholinergic deficit, based mainly on post- mortem examination of the brain at the end stages of the illness. Pharmacologic enhancement of the cholinergic system has not been consistently efficacious and does not stop disease progression. Animal and human models of AD based on inducted cholinergic hypofunction only mimic some aspects of symptomatology in AD. More recent neuropathologic studies have reported deficits in other neurotransmitter systems (e.g. dopamine, serotonin, norepinephrine). As an integration of the present knowledge concerning the neurochemistry of AD and the observation that neurotransmitter systems function synergistically, not in isolation, the proposed studies will test the novel hypothesis that the cognitive and behavioral symptomatology in AD represents a failure of acetylcholine to modulate other functionally-linked neurotransmitters, and that these deficits occur prior to the clinical diagnosis of AD. A recently developed research approach with Positron Emission Tomography (PET) will be used to combine neuroreceptor radiotracer studies with pharmacologic challenges to measure cholinergic modulation (Smith et al., 1996, Dewey et al., 1993). This approach is the most direct, non-invasive and quantitative method of measuring neurotransmitter activity and modulation in the living brain. These studies will measure cholinergic modulation of monoamine function (serotonin, dopamine) in the normal elderly, and in AD patients. A well- characterized pharmacologic challenge paradigm (administration of the selective muscarinic cholinegic antagonist scopolamine) will be used with PET and radiotracers for dopaminergic (D2, [1]C]- raclopride) and serotonergic (5-HT2A, [18F]-altanserin) receptors. Having performed the proposed studies, unique information will be obtained regarding cholinergic modulation of dopamine and serotonin receptor systems. These studies will provide a baseline for subsequent longitudinal follow-up of patients and for correlation with genetics and post-mortem findings (by the Alzheimer~s Disease Research Center) to determine how differences in monoaminergic responsiveness relate to AD subgroups (e.g. Lewy Body Dementia) A better understanding of the neurochemical deficits in AD may direct the development of novel treatment interventions that would improve symptomatology and perhaps stop disease progression.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
1R01MH057078-01
Application #
2035708
Study Section
Mental Disorders of Aging Review Committee (MDA)
Project Start
1997-04-01
Project End
2001-03-31
Budget Start
1997-04-01
Budget End
1998-03-31
Support Year
1
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Psychiatry
Type
Schools of Medicine
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Marano, Christopher M; Workman, Clifford I; Lyman, Christopher H et al. (2014) The relationship between fasting serum glucose and cerebral glucose metabolism in late-life depression and normal aging. Psychiatry Res 222:84-90
Marano, Christopher M; Workman, Clifford I; Kramer, Elisse et al. (2013) Longitudinal studies of cerebral glucose metabolism in late-life depression and normal aging. Int J Geriatr Psychiatry 28:417-23
Munro, Cynthia A; Workman, Clifford I; Kramer, Elisse et al. (2012) Serotonin modulation of cerebral glucose metabolism: sex and age effects. Synapse 66:955-64
Diaconescu, Andreea Oliviana; Kramer, Elisse; Hermann, Carol et al. (2011) Distinct functional networks associated with improvement of affective symptoms and cognitive function during citalopram treatment in geriatric depression. Hum Brain Mapp 32:1677-91
Smith, Gwenn S; Workman, Clifford I; Kramer, Elisse et al. (2011) The relationship between the acute cerebral metabolic response to citalopram and chronic citalopram treatment outcome. Am J Geriatr Psychiatry 19:53-63
Smith, Gwenn S; Ma, Yilong; Dhawan, Vijay et al. (2009) Selective serotonin reuptake inhibitor (SSRI) modulation of striatal dopamine measured with [11C]-raclopride and positron emission tomography. Synapse 63:1-6
Smith, Gwenn S; Reynolds 3rd, Charles F; Houck, Patricia R et al. (2009) Cerebral glucose metabolic response to combined total sleep deprivation and antidepressant treatment in geriatric depression: a randomized, placebo-controlled study. Psychiatry Res 171:1-9
Smith, Gwenn S; Kramer, Elisse; Hermann, Carol et al. (2009) Serotonin modulation of cerebral glucose metabolism in depressed older adults. Biol Psychiatry 66:259-66
Smith, Gwenn S; Kramer, Elisse; Ma, Yilong et al. (2009) The functional neuroanatomy of geriatric depression. Int J Geriatr Psychiatry 24:798-808
Smith, Gwenn S; Kramer, Elisse; Ma, Yilong et al. (2009) Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease. Brain 132:392-401

Showing the most recent 10 out of 19 publications